NCT07136831

Brief Summary

this study aims to assess the short-term (3-month) clinical and echocardiographic outcomes of primary PCI among STEMI patients from rural versus urban areas in Upper Egypt. A special focus will be placed on identifying predictors of MACE. The findings may offer valuable insight into optimizing STEMI care pathways and support the development of regional STEMI networks across Egypt.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
162

participants targeted

Target at P50-P75 for all trials

Timeline
8mo left

Started Aug 2025

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress53%
Aug 2025Dec 2026

First Submitted

Initial submission to the registry

July 28, 2025

Completed
18 days until next milestone

Study Start

First participant enrolled

August 15, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 22, 2025

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 15, 2026

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2026

Last Updated

August 22, 2025

Status Verified

August 1, 2025

Enrollment Period

1.2 years

First QC Date

July 28, 2025

Last Update Submit

August 14, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Incidence of major adverse cardiovascular events (MACE) among STEMI patients undergoing primary percutaneous coronary intervention (PCI),

    Unite of measurement : Number of patients experiencing MACE (% of total)

    3 month

Interventions

A catheter-based invasive procedure used to open blocked coronary arteries in patients presenting with ST-elevation myocardial infarction (STEMI).

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

patients Confirmed diagnosis of ST-segment elevation myocardial infarction (STEMI) based on ECG and cardiac biomarkers.

You may qualify if:

  • \. Adults aged ≥18 years. 2. Confirmed diagnosis of ST-segment elevation myocardial infarction (STEMI) based on ECG and cardiac biomarkers.
  • \. Underwent primary percutaneous coronary intervention (PCI) within the study period.
  • \. Known and verified residential address classified as rural or urban based on official definitions (e.g., UK or WHO classification).
  • \. Informed consent obtained

You may not qualify if:

  • Non-STEMI or unstable angina cases.
  • Patients who received fibrinolytic therapy instead of PCI.
  • Transfer from another facility after more than 12 hours of symptom onset.
  • Patients with previous revascularization (e.g., CABG or PCI within the last 6 months).
  • Incomplete clinical data or unknown residential location.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Links

Central Study Contacts

Fatma ali khallaf Dr fatma ali

CONTACT

Hatem Abdelrahman, Professor

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
3 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

July 28, 2025

First Posted

August 22, 2025

Study Start

August 15, 2025

Primary Completion (Estimated)

October 15, 2026

Study Completion (Estimated)

December 30, 2026

Last Updated

August 22, 2025

Record last verified: 2025-08